Vasculotoxic effects of insulin and its role in atherosclerosis: What is the evidence?

Current Atherosclerosis Reports

Volumn 13, Issue 2, 2011, Pages 123-128

  Nandish, Shailesh ^a   Bailon, Oscar ^a   Wyatt, Jamison ^a   Smith, John ^a   Stevens, Adrienne ^a   Lujan, Mike ^a   Chilton, Robert ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Atherothrombotic risk; Cancer; Cardiovascular; Insulin; Type 2 diabetes

Indexed keywords

BIPHASIC INSULIN; FIBRINOGEN; GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN GLARGINE; LONG ACTING INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; SULFONYLUREA; TRANSCRIPTION FACTOR FKHR;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE VARIABILITY; BREAST CANCER; CALORIC INTAKE; CANCER RISK; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG EFFECT; DRUG MECHANISM; DRUG TREATMENT FAILURE; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERCOAGULABILITY; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SYNTHESIS; LIFESTYLE MODIFICATION; MOLECULAR DYNAMICS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; TOXICITY; VASCULOTOXICITY; WEIGHT CHANGE; WEIGHT CONTROL; WEIGHT GAIN;

AGED; ATHEROSCLEROSIS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 79955911852     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-011-0165-4     Document Type: Review

References (26)

1. Faramarz Ismail-Beigi MD, Timothy Craven MSPH, Mary Ann Banerji MD, Jan Basile MD. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. The Lancet, Volume 376, Issue 9739, Pages 419-30. This trial brings into question the protection of microvascular events with good glucose control. Thoughtful questions arise in this recent publication with comparison to older trials.
2. Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol. 2010 Jul;7(7):369-75. This is an excellent quick overview of the recent trials using intensive glycemic control. It has quick charts to read with important contrasts between trials.
3. Schernthaner G. Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr. 2010 Jan;160(1-2):8-19.
4. Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes 1993;42:1700-07.
5. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes-causes,effects and coping strategies. Diabetes Obes Metab. 2007 Nov;9(6):799-812. Review.
6. Greet Van den Berghe. J. Clin. Invest. 114:1187-95 (2004).
7. The DCCT Research Group. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care. 1988;11:567-73.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
9. Randeree H, Omar M, Motala A, Seedat M. Effect of insulin therapy of blood pressure NIDDM patients with secondary failure, Diabetes Care. 1992;15:1258-63.
10. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA. 1998 Jul 8;280(2):140-6. Erratum in: JAMA 1998 Nov 4;280(17):1484.
11. Matsumoto M, Han S, Kitamura T, Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest. 2006 Sep;116(9):2464-72. Epub 2006 Aug 10. (Pubitemid 44330145)
12. Unger RH. How obesity causes diabetes in Zucker diabetic fatty rats. Trends Endocrinol Metab. 1997 Sep;8(7):276-82. (Pubitemid 27424205)
13. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008 Feb;7(2):95-6. Review.
14. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-41.
15. Emanuele N. Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Arch Intern Med. 1998;158:2485-90.
16. Bastard JP, Piéroni L. Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity. Biomed Pharmacother. 1999 Dec;53(10):455-61. (Pubitemid 30019381)
17. Coughlin SS et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160-7. (Pubitemid 38747263)
18. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate and pancreas. Gastroenterology. 2007;132:2208-25. (Pubitemid 46693749)
19. Larsson SC, Orsini N, Wolk A. Diabetes and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(1679-1687):3.
20. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(2076-2083):4.
21. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121:856-62. (Pubitemid 47106217)
22. Bowker SL et al. Increased cancer-related mortality for patients with T2D who use sulfonylureas or insulin. Diabetes Care. 2006;29:254-8. (Pubitemid 44106500)
23. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdò ttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009 Sep;52(9):1745-54. Epub 2009 Jul 9.
24. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009 Sep;52(9):1766-77. Epub 2009 Jul 2.
25. Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009 Sep;52(9):1755-65. Epub 2009 Jul 15.
26. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein- 3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004 Apr 24;363(9418):1346-53. Review.